July 20, 2016
Bristol-Myers Squibb said on July 18 that the US FDA and the European Medicines Agency (EMA) have accepted its filings that seek a head and neck cancer indication for its immune checkpoint inhibitor Opdivo (nivolumab). The filings both carry an...read more